APTO vs. ESLA, INKT, DTIL, OKYO, ELEV, PASG, CLDI, SRZN, JATT, and COEP
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), Precision BioSciences (DTIL), OKYO Pharma (OKYO), Elevation Oncology (ELEV), Passage Bio (PASG), Calidi Biotherapeutics (CLDI), Surrozen (SRZN), JATT Acquisition (JATT), and Coeptis Therapeutics (COEP). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences vs.
Aptose Biosciences (NASDAQ:APTO) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
In the previous week, Aptose Biosciences had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Aptose Biosciences and 6 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.25 beat Aptose Biosciences' score of 0.15 indicating that Estrella Immunopharma is being referred to more favorably in the news media.
Aptose Biosciences has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Estrella Immunopharma's return on equity of -195.77% beat Aptose Biosciences' return on equity.
Aptose Biosciences received 381 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. However, 100.00% of users gave Estrella Immunopharma an outperform vote while only 62.42% of users gave Aptose Biosciences an outperform vote.
26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 1.3% of Aptose Biosciences shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aptose Biosciences currently has a consensus target price of $4.33, suggesting a potential upside of 2,573.25%. Estrella Immunopharma has a consensus target price of $16.00, suggesting a potential upside of 981.08%. Given Aptose Biosciences' higher possible upside, equities analysts plainly believe Aptose Biosciences is more favorable than Estrella Immunopharma.
Estrella Immunopharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Aptose Biosciences and Estrella Immunopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:APTO) was last updated on 2/22/2025 by MarketBeat.com Staff
